Novel biomarkers in bladder cancer

Area of Science:

• Oncology
• Genitourinary Cancer Research
• Translational Medicine

Background:

• Metastatic urothelial bladder cancer treatment has evolved with new FDA-approved immune checkpoint inhibitors.
• Genomic characterization reveals potential targets for small molecule inhibitors.
• Molecular subtyping of urothelial carcinoma impacts treatment response, an active research area.

Purpose of the Study:

• To highlight research on validating and discovering novel biomarkers.
• To advance precision oncology in bladder cancer treatment.
• To address the unmet need for predictive biomarkers of therapy response.

Main Methods:

• Review of recent research findings in bladder cancer.
• Analysis of genomic and transcriptomic data.
• Focus on biomarker discovery and validation.

Main Results:

• Identification of multiple immune checkpoint blockade agents for advanced disease.
• Discovery of numerous potential therapeutic targets through genomic analysis.
• Advancements in molecular subtyping influencing treatment strategies.

Conclusions:

• Significant progress in bladder cancer treatment options.
• Ongoing need for predictive biomarkers to guide therapy selection.
• Precision oncology holds promise for improving patient outcomes in bladder cancer.